CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice

Journal of Neurochemistry

Volumn 124, Issue 5, 2013, Pages 613-620

  Giuliani, Alessandro ^a   Beggiato, Sarah ^b   Baldassarro, Vito A ^a   Mangano, Chiara ^a,c   Giardino, Luciana ^a,c   Imbimbo, Bruno P ^d   Antonelli, Tiziana ^b,c   Calzà, Laura ^a,c   Ferraro, Luca ^b,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c IRET ONLUS Foundation Ozzano Emilia   (Italy)

^d Research and Development   (Italy)

Author keywords

Alzheimer's disease; GABA; glutamate; LY450139; novel object recognition; synaptosomes

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CARBOXYLIC ACID DERIVATIVE; CHF 5074; POTASSIUM ION; SEMAGACESTAT; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; ACETYLCHOLINE RELEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FRONTAL CORTEX; IN VIVO STUDY; LONG TERM MEMORY; MEMORY DISORDER; MOUSE; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RECOGNITION; SENILE PLAQUE; SYNAPTOSOME; TREATMENT OUTCOME; VISUAL MEMORY; WILD TYPE;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; CEREBRAL CORTEX; CYCLOPROPANES; DISEASE MODELS, ANIMAL; FEMALE; FLURBIPROFEN; HUMANS; MEMORY; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; SYNAPTOSOMES;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84874116487     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12136     Document Type: Article

References (47)

1. Ardiles A. O., Tapia-Rojas C. C., Mandal M., Alexandre F., Kirkwood A., Inestrosa N. C., and, Palacios A. G., (2012) Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 109, 13835-13840.
2. Arendt T., (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 118, 167-179.
3. Balducci C., Mehdawy B., Mare L., et al,. (2011) The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J. Alzheimers Dis. 24, 799-816.
4. Benilova I., Karran E., and, De Strooper B., (2012) The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357.
5. Berg L., McKeel D. W., Jr, Miller J. P., et al,. (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55, 326-335. (Pubitemid 28146197)
6. Blennow K., Bogdanovic N., Alafuzoff I., Ekman R., and, Davidsson P., (1996) Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J. Neural Transm. 103, 603-618. (Pubitemid 26383646)
7. Bradford M. M., (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal. Biochem. 72, 248-254.
8. Cheng S., Li L., He S., Liu J., Sun Y., He M., Grasing K., Premont R. T., and, Suo W. Z., (2010) GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity. J. Biol. Chem. 285, 41541-41548.
9. Chiodi V., Uchigashima M., Beggiato S., et al,. (2012) Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 45, 983-991.
10. Christensen D. Z., Kraus S. L., Flohr A., Cotel M. C., Wirths O., and, Bayer T. A., (2008) Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 116, 647-655.
11. Comery T. A., Martone R. L., Aschmies S., et al,. (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25, 8898-8902. (Pubitemid 41384457)
12. Dong H., Csernansky C. A., Martin M. V., Bertchume A., Vallera D., and, Csernansky J. G., (2005) Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology 181, 145-152. (Pubitemid 41440925)
13. Ferraro L., Beggiato S., Marcellino D., Frankowska M., Filip M., Agnati L. F., Antonelli T., Tomasini M. C., Tanganelli S., and, Fuxe K., (2010) Nanomolar concentrations of cocaine enhance D2-like agonist-induced inhibition of the K+-evoked [3H]-dopamine efflux from rat striatal synaptosomes: a novel action of cocaine. J. Neural Transm. 117, 593-597.
14. Giannakopoulos P., Herrmann F. R., Bussière T., Bouras C., Kövari E., Perl D. P., Morrison J. H., Gold G., and, Hof P. R., (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500. (Pubitemid 36559525)
15. Giannakopoulos P., Kövari E., Gold G., von Gunten A., Hof P. R., and, Bouras C., (2009) Pathological substrates of cognitive decline in Alzheimer's disease. Front. Neurol. Neurosci. 24, 20-29.
16. Hardy J., and, Allsop D., (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388.
17. Hardy J. A., Higgins G. A., (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
18. Henley D. B., May P. C., Dean R. A., and, Siemers E. R., (2009) Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin. Pharmacother. 10, 1657-1664.
19. Heredia L., Torrente M., Colomina M. T., and, Domingo J. L., (2012) Behavioral effects of oral subacute exposure to BDE-209 in young adult mice: a preliminary study. Food Chem. Toxicol. 50, 707-712.
20. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and, Cole G., (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. (Pubitemid 26332733)
21. Imbimbo B. P., Del Giudice E., Colavito D., et al,. (2007) 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl) -cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822-830. (Pubitemid 350146064)
22. Imbimbo B. P., Hutter-Paier B., Villetti G., Facchinetti F., Cenacchi V., Volta R., Lanzillotta A., Pizzi M., and, Windisch M., (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 156, 982-993.
23. Imbimbo B. P., Giardino L., Sivilia S., et al,. (2010) CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 20 (1), 159-173.
24. Jazi R., Lalonde R., Qian S., and, Strazielle C., (2009) Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice. Neurosci. Res. 63, 106-114.
25. Karanth S., Liu J., Mirajkar N., and, Pope C., (2006) Effects of acute chlorpyrifos exposure on in vivo acetylcholine accumulation in rat striatum. Toxicol. Appl. Pharmacol. 216, 150-156. (Pubitemid 44402637)
26. Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H., and, Younkin S. G., (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381. (Pubitemid 32107428)
27. Klingner M., Apelt J., Kumar A., Sorger D., Sabri O., Steinbach J., Scheunemann M., and, Schliebs R., (2003) Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. Int. J. Dev. Neurosci. 21, 357-369. (Pubitemid 37346400)
28. Knobloch M., Konietzko U., Krebs D. C., and, Nitsch R. M., (2007) Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice. Neurobiol. Aging 28, 1297-1306. (Pubitemid 47081235)
29. Lue L. F., Kuo Y. M., Roher A. E., Brachova L., Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E., and, Rogers J., (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862. (Pubitemid 29426831)
30. Mangialasche F., Solomon A., Winblad B., Mecocci P., and, Kivipelto M., (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716.
31. McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I., and, Masters C. L., (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.
32. Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K., and, Matsuoka N., (2012) Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 2037-2050.
33. Moreno E., Vaz S. H., Cai N. S., et al,. (2011) Dopamine-galanin receptor heteromers modulate cholinergic neurotransmission in the rat ventral hippocampus. J. Neurosci. 31, 7412-7423.
34. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., and, Nabeshima T., (2007) Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 21, 2135-2148. (Pubitemid 47026449)
35. Penzes P., and, Vanleeuwen J. E., (2011) Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease. Brain Res. Rev. 67, 184-192.
36. Peretto I., Radaelli S., Parini C., et al,. (2005) Synthesis and biological activity of flubiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J. Med. Chem. 48, 5705-5720. (Pubitemid 41298345)
37. Puoliväli J., Wang J., Heikkinen T., Heikkilä M., Tapiola T., van Groen T., and, Tanila H., (2002) Hippocampal Aβ 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol. Dis. 9, 339-347. (Pubitemid 34442081)
38. Raiteri L., Luccini E., Romei C., Salvadori S., and, Calò G., (2009) Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br. J. Pharmacol. 157, 474-481.
39. Schliebs R., and, Arendt T., (2011) The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 221, 555-563.
40. Scholtzova H., Wadghiri Y. Z., Douadi M., Sigurdsson E. M., Li Y. S., Quartermain D., Banerjee P., and, Wisniewski T., (2008) Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J. Neurosci. Res. 86, 2784-2791.
41. Schor N. F., (2011) What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann. Neurol. 69, 237-239.
42. Selkoe D. J., (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113.
43. Shankar G. M., Li S., Mehta T. H., et al,. (2008) Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842.
44. Watanabe T., Yamagata N., Takasaki K., Sano K., Hayakawa K., Katsurabayashi S., Egashira N., Mishima K., Iwasaki K., and, Fujiwara M., (2009) Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. 1249, 222-228.
45. Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G., and, Ashe K. H., (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867. (Pubitemid 35386304)
46. Wolfe M. S., (2012) γ-Secretase inhibitors and modulators for Alzheimer's disease. J. Neurochem. 120 (Suppl 1), 89-98.
47. Zhang W., Bai M., Xi Y., Hao J., Liu L., Mao N., Su C., Miao J., and, Li Z., (2012) Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction. Free Radic. Biol. Med. 52, 1443-1452.